NCT03874858 - A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

Nilotinib

Nilotinib oral 300 mg QD hard capsules

DRUG

Nilotinib

Nilotinib oral 300 mg BID hard capsules

DRUG

Asciminib

Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)

Trial Locations (26)

10043

Novartis Investigative Site, Orbassano

10126

Novartis Investigative Site, Torino

10128

Novartis Investigative Site, Torino

16132

Novartis Investigative Site, Genova

20122

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

28100

Novartis Investigative Site, Novara

37134

Novartis Investigative Site, Verona

40138

Novartis Investigative Site, Bologna

42123

Novartis Investigative Site, Reggio Emilia

50134

Novartis Investigative Site, Florence

53100

Novartis Investigative Site, Siena

56126

Novartis Investigative Site, Pisa

65124

Novartis Investigative Site, Pescara

70124

Novartis Investigative Site, Bari

80131

Novartis Investigative Site, Napoli

84131

Novartis Investigative Site, Salerno

88100

Novartis Investigative Site, Catanzaro

90127

Novartis Investigative Site, Palermo

90146

Novartis Investigative Site, Palermo

95123

Novartis Investigative Site, Catania

09121

Novartis Investigative Site, Cagliari

06129

Novartis Investigative Site, Perugia

00144

Novartis Investigative Site, Roma

00161

Novartis Investigative Site, Roma

00168

Novartis Investigative Site, Roma